FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Williams Rosemary Y.					2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC BLCM										Check	k all appli Directo Officer	all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2020										VP, Finance & PAO					
(Street) HOUSTON TX 77030 (City) (State) (Zip)				_ 4. II -	4. If Amenament, Date of Original Filed (Month/Day/Year)											e)				
(5)			- Dorin			i+	ioo A		inad I					nofici	مالي	0				
1. Title of Security (Instr. 3) 2. Transac Date					ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transac Code (Ir	tion	4. Securities Acquired (A)				5. Amor Securiti Benefic Owned		nt of es ally Following	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
								-	Code	v	Amount			Price	•	Transact	tion(s)			(Instr. 4)
Common Stock 01/02					0				М		1,28	2	A	(1	1)	5,753			D	
Common Stock)1/02/2020					F ⁽²⁾		483		D	\$1	.51	5,270			D	
Common Stock 01)3/2020					M		781		A	(1	1)	6,051			D	
Common Stock 01/03				3/2020	0				F ⁽³⁾		295		D	\$1.4		5,756			D	
	Т															wned				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Date,			n of			oiration I	Date		Amou Secu Unde Deriv	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (Ir	erivative ecurity	derivative Securities Beneficial Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)					Title	or Numbe of	r						
(1)	01/02/2020			M			1,282		(4)		(4)			1,282	!	\$0	2,562		D	
	(Fi LICUM PH HOLCOMI ON T2 (St Security (Inst Stock Stock Stock Stock 2. Conversion or Exercise Price of Derivative Security	(First) (LICUM PHARMACEUTICHOLCOMBE BLVD., STE DN TX (State) Tab Security (Instr. 3) Stock Stock Stock Stock T 2. Conversion or Exercise Price of Derivative Security Security Security Stock Stock T A. Transaction Date (Month/Day/Year)	(First) (Middle) LICUM PHARMACEUTICALS, IN HOLCOMBE BLVD., STE. 800 ON TX 77030 (State) (Zip) Table I - Not Security (Instr. 3) Stock Stock Stock Stock Table II - 2. Conversion or Exercise Price of Derivative Security (Month/Day/Year) (Month/Day/Year) Stock Table II -	(First) (Middle) LICUM PHARMACEUTICALS, INC. HOLCOMBE BLVD., STE. 800 Table I - Non-Deriv Security (Instr. 3) Stock Stock O1/02 Stock O1/03 Table II - Deriva (e.g., p. price of Derivative Security (Month/Day/Year) 3. Transaction Date (Month/Day/Year) (Month/Day/Year)	IS Rosemary Y. (First) (Middle) LICUM PHARMACEUTICALS, INC. HOLCOMBE BLVD., STE. 800 Table I - Non-Derivative Security (Instr. 3) 2. Transaction Date (Month/Day/Year) Stock 10/02/2020 Stock 10/03/2020 Table II - Derivative Security 2. Transaction Date (Month/Day/Year) Stock 10/03/2020 Table II - Derivative Security A. Transaction Date (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) Stock Code (Month/Day/Year) Code (Month/Day/Year)	Security (Instr. 3) Security (Instr. 3)	Security (Instr. 3) Stock O1/02/2020	Security (Instr. 3) Securities Accurative Securities Accurative Security (Instr. 3) Securities Accurate (Instr. 3) Securities Acquired (Instr. 3)	Security (Instr. 3) Security (Instr. 3)	Security (Instr. 3) Stock O1/02/2020 Month/Day/Year O1/03/2020 O1/03/2020	Stock O1/02/2020 M Stock O1/03/2020 Table - Derivative Securities Acquired, Disposed of Exercise Price of Derivative Security O1/03/2020 M Stock O1/03/2020 Stock O1/03/2020	Security (Instr. 3) Stock O1/02/2020 M O1/03/2020 O1/	Security (Instr. 3) Security (Instr. 3)	BELLICUM PHARMACEUTICALS, INC. BLCM	Security (Instr. 3) Security (Instr. 3)	Check Stock Stoc	BELLICUM PHARMACEUTICALS, INC. (First) (Middle) J. LICUM PHARMACEUTICALS, INC. HOLCOMBE BLVD., STE. 800 A. If Amendment, Date of Original Filed (Month/Day/Year) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Stock 01/02/2020 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owner (e.g., puts, calls, warrants, options, convertible securities) Conversion Date (Month/Day/Year) Amount of Shares Amount of Shares	SECURITY (Instr. 3) Security (Instr. 3) Security (Instr. 3) Stock O1/02/2020 Stock O1/03/2020 Stock	SEROSEMATY Y.	BELLICUM PHARMACEUTICALS, INC. BUCM Stock Stoc

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.

01/03/2020

2. Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 5,125 shares.

781

- 3. Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 3,125 shares.
- 4. On January 2, 2018, the reporting person was granted 5,125 RSUs, of which 1,282 vested on January 2, 2020. The RSUs vest in four annual installments beginning January 2, 2019.
- 5. On January 3, 2017, the reporting person was granted 3,125 RSUs, of which 781 vested on January 3, 2020. The RSUs vest in four annual installments beginning January 3, 2018.

Remarks:

Stock

/s/ Rosemary Y. Williams

781

Stock

** Signature of Reporting Person

Date

01/06/2020

781

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.